This midcap pharma stock soared 5% despite a weak market on July 11; Know its targets here

This midcap pharma stock soared 5% despite a weak market on July 11; Know its targets here

by 5paisa Research Team Last Updated: 2022-07-11T12:18:33+05:30

GRANULES rose over 5% on July 11 and has outperformed the pharma index.

Granules India Limited is a pharmaceutical company, engaged in the business of manufacturing finished dosages and APIs. Based in Hyderabad, it is one of the strong growing midcap companies in its sector.

The stock of Granules India Ltd witnessed a strong breakout from its stiff resistance level of Rs 285 and soared over 5% on Monday. With this, it has taken out near-term resistance and is above its 100-DMA. Interestingly, the stock has jumped about 30% after it formed a double-bottom pattern in just 15 trading sessions. The level of Rs 226 has acted as strong support and the stock saw a good buying interest at this level. It is now inches away from testing its 200-DMA level of Rs 300. Also with its bullish price structure, the volumes have been on a rise recently, which indicates increasing buying momentum in the stock.

After its short-term bull run, the stock has seen all its technical indicators pointing in the north direction. The daily 14-period RSI (66.05) has entered bullish territory and is above its prior swing high. The MACD line is above the signal line and signals an uptrend. Meanwhile, the OBV has also improved, and strong volumetric strength has been seen. The Relative Strength (RS) is in the positive zone and indicates outperformance of the stock against the broader market. Meanwhile, the Elder Impulse System, along with TSI and KST indicators maintain a bullish view of this stock. In short, the stock is expected to move higher from here on.

Considering the price pattern, we can expect the stock to test the level of Rs 320, followed by Rs 350 in the medium term. But during this volatile market condition, the stock might see some weakness if it falls below the 20-DMA level of Rs 260. It provides good trading opportunities in the near term. So keep a watch on the above-mentioned levels.

Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial. Also, The

Open Free Demat Account

& get benefits worth 2100*

Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number